Prelude Therapeutics (PRLD) to Release Earnings on Tuesday

Prelude Therapeutics (NASDAQ:PRLD - Get Free Report) is projected to announce its Q1 2025 earnings results before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.48) per share for the quarter.

Prelude Therapeutics (NASDAQ:PRLD - Get Free Report) last issued its quarterly earnings data on Monday, March 10th. The company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.11. The company had revenue of $4.00 million for the quarter. On average, analysts expect Prelude Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Prelude Therapeutics Stock Down 3.4 %

PRLD stock traded down $0.03 during mid-day trading on Friday, reaching $0.89. The company had a trading volume of 85,025 shares, compared to its average volume of 268,290. The stock's 50-day simple moving average is $0.75 and its two-hundred day simple moving average is $1.01. The stock has a market capitalization of $50.10 million, a P/E ratio of -0.50 and a beta of 1.35. Prelude Therapeutics has a one year low of $0.61 and a one year high of $6.80.

Analyst Ratings Changes

A number of research analysts have issued reports on PRLD shares. HC Wainwright reissued a "buy" rating and set a $5.00 target price on shares of Prelude Therapeutics in a research note on Tuesday, April 8th. JMP Securities reiterated a "market outperform" rating and set a $4.00 price objective on shares of Prelude Therapeutics in a research report on Tuesday.

Insider Activity

In related news, CEO Krishna Vaddi purchased 47,500 shares of the company's stock in a transaction on Wednesday, March 12th. The shares were bought at an average cost of $0.71 per share, for a total transaction of $33,725.00. Following the transaction, the chief executive officer now owns 1,214,775 shares of the company's stock, valued at $862,490.25. This represents a 4.07 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, insider Andrew Combs acquired 100,000 shares of the firm's stock in a transaction dated Tuesday, March 25th. The stock was bought at an average price of $0.69 per share, with a total value of $69,000.00. Following the completion of the acquisition, the insider now directly owns 480,123 shares of the company's stock, valued at approximately $331,284.87. This represents a 26.31 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 822,500 shares of company stock valued at $568,475. Company insiders own 62.80% of the company's stock.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.